Cargando…

The evolving role and utility of off-label drug use in multiple myeloma

The treatment landscape for multiple myeloma (MM) has dramatically changed over the last three decades, moving from no US Food and Drug Administration approvals and two active drug classes to over 19 drug approvals and at least eight different active classes. The advances seen in MM therapy have rel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stoeckle, James H, Davies, Faith E, Williams, Louis, Boyle, Eileen M, Morgan, Gareth J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Open Exploration 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400732/ https://www.ncbi.nlm.nih.gov/pubmed/36046752 http://dx.doi.org/10.37349/etat.2021.00050

Ejemplares similares

Insights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancer
por: Ghamlouch, Hussein, et al.
Publicado: (2021)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Structural variants shape the genomic landscape and clinical outcome of multiple myeloma
por: Ashby, Cody, et al.
Publicado: (2022)

Evolving treatment strategies for myeloma
por: Morgan, G J, et al.
Publicado: (2005)

Evolving therapeutic role of bisphosphonates in multiple myeloma
por: Ural, A U, et al.
Publicado: (2005)

Off-label drugs for obesity
por: Morgan, Andy, et al.
Publicado: (2022)

Reply to letters on review ‘Evolving treatment strategies for myeloma’
por: Morgan, G J, et al.
Publicado: (2005)

A proof-of-concept study for the pathogenetic role of enhancer hypomethylation of MYBPHL in multiple myeloma
por: Wong, Kwan Yeung, et al.
Publicado: (2021)

Tocilizumab: Progression of multiple myeloma following off-label use: case report
Publicado: (2021)

The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
por: Boyle, Eileen M., et al.
Publicado: (2021)

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
por: Jackson, Graham H, et al.
Publicado: (2019)

Differential RNA splicing as a potentially important driver mechanism in multiple myeloma
por: Bauer, Michael A., et al.
Publicado: (2020)

Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
por: Pawlyn, Charlotte, et al.
Publicado: (2018)

Multiple drugs: Various toxicities, off-label use and no response to off-label therapy: case report
Publicado: (2021)

MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma
por: Qiang, Ya-Wei, et al.
Publicado: (2018)

Multiple drugs: Drugs ineffective and off-label use: case report
Publicado: (2022)

Heat shock proteins in multiple myeloma
por: Zhang, Lei, et al.
Publicado: (2014)

Hyperhaploid karyotypes in multiple myeloma
por: Sawyer, Jeffrey R., et al.
Publicado: (2017)

Evolving role of high dose stem cell therapy in multiple myeloma
por: Gupta, Ajay, et al.
Publicado: (2011)

The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma
por: Mikulasova, Aneta, et al.
Publicado: (2017)

Multiple drugs: Lymphocytopenia and off-label use: case report
Publicado: (2020)

Multiple drugs: Bradycardia and off-label use: case report
Publicado: (2021)

Multiple drugs: No response and off label use: case report
Publicado: (2021)

Multiple drugs: No response and off-label use: case report
Publicado: (2021)

Multiple drugs: Infections and off label use: case report
Publicado: (2021)

Multiple drugs: No improvement and off label use: case report
Publicado: (2022)

Drug utilization in neonatal setting of Pakistan: focus on unlicensed and off label drug prescribing
por: Aamir, Muhammad, et al.
Publicado: (2018)

Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial
por: Bird, Sarah, et al.
Publicado: (2021)

Characterization of a Novel Mouse Model of Multiple Myeloma and Its Use in Preclinical Therapeutic Assessment
por: Fryer, Rosemary A., et al.
Publicado: (2013)

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
por: Davies, Faith E., et al.
Publicado: (2022)

Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf
por: Barilà, Gregorio, et al.
Publicado: (2021)

Update on the optimal use of bortezomib in the treatment of multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2017)

APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma
por: Walker, Brian A, et al.
Publicado: (2015)

Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
por: Jackson, Graham H, et al.
Publicado: (2019)

Multiple drugs: Lack off efficacy following off-label use: 2 case reports
Publicado: (2022)

Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myeloma
por: Mitchell, Jonathan S., et al.
Publicado: (2015)

Utilization of biotechnological drugs in rare diseases requiring the use of off-label drugs in children in Turkey
por: KIRMIZI, N. İpek, et al.
Publicado: (2021)

Multiple drugs: Various toxicities and off-label use: case report
Publicado: (2020)

Multiple drugs: Lack of efficacy and off-label use: case report
Publicado: (2020)

Multiple drugs: Liver injury and Off-label-use: case report
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_votd3ksuevk825k9l7fl9cotf0